Solu Therapeutics, a clinical-stage biotech focused on cancer and immunology, is valued at $100 million following its $41 million Series A, CEO Philip Vickers tells Axios exclusively.
Why it matters: Solu could start raising a Series B round as early as year-end if the company produces positive clinical data, he says.
